Intervacc

Stockholm, November 11, 2024 - Intervacc AB (publ) will publish its interim report for the period January to September 2024 on Thursday 14 November 2024, at 08:30 CET. CEO Jonas Sohlman and CFO Jan Persson will present the report at a conference call and audiocast held on the same day at 11:00 CET.

If you wish to participate via the audiocast, please go to the link below.

https://intervacc.videosync.fi/intervacc-q3-report-2024

If you prefer to participate via conference call, please register using the link below. After registration, you will receive a phone number and a conference ID to log in to the conference. Through the telephone conference, there is an opportunity to ask questions verbally.

https://conference.financialhearings.com/teleconference/?id=5009525

For more information please contact:  

Jonas Sohlman, CEO

Phone: +46 (0)8 120 10 600

E-mail: jonas.sohlman@intervacc.se

The information was submitted for publication, through the agency of the contact person set out above on November 11, 2024, 15.45 p.m. CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Sciences where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 - 684 211 10